ストックスクリーナーアプリを入手
4.1168
2.15%
-0.0732
前日終値:
$4.19
開ける：
$4.2
24時間の取引高:
32,096
Relative Volume:
0.04
時価総額：
$532.07M
収益：
$201.49M
当期純損益:
$-66.54M
株価収益率:
-7.9215
EPS:
-0.5197
ネットキャッシュフロー:
$-8.88M
1週間 パフォーマンス:
+2.24%
1か月 パフォーマンス:
-11.26%
6か月 パフォーマンス:
-23.08%
1年 パフォーマンス:
+48.01%
1日の値動き範囲:
$4.105
$4.20
1週間の範囲:
$3.702
$4.3051
52週間の値動き範囲:
$2.6209
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
名前
Cytek Biosciences Inc
セクター
電話
(877) 922-9835
住所
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.12 | 541.11M | 201.49M | -66.54M | -8.88M | -0.5197 |
ABT
Abbott Laboratories
|
86.53 | 149.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
303.22 | 116.96B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
74.47 | 94.76B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.27 | 71.81B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.80 | 49.79B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-05-09 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-31 | ダウングレード | Goldman | Buy → Sell |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-07-19 | 開始されました | Raymond James | Mkt Perform |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
すべてを表示
Cytek Biosciences Inc (CTKB) 最新ニュース
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo
Cytek Biosciences launches on-demand webinar on hMSC variation impacting regenerative medicine - Traders Union
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming - Moomoo
Cytek Biosciences schedules webinar to advance deep immunophenotyping techniques - Traders Union
Cytek Biosciences Q1 2026 Earnings: Deep EPS Miss Fails to Dampen Investor SentimentPre-Announcement Alert - Newser
Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting - Stock Titan
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock - Stock Titan
Cytek Biosciences (CTKB) CTO vests RSUs, holds 4,919,617 shares - Stock Titan
Cytek Biosciences (CTKB) SVP nets shares after RSU vesting and tax withholding - Stock Titan
Cytek Biosciences (CTKB) CEO reports RSU vesting and tax share withholding - Stock Titan
Cytek (CTKB) CFO nets shares from RSU vesting, surrenders stock for taxes - Stock Titan
Cytek Biosciences (CTKB) CLO gains shares after RSU vesting - Stock Titan
Cytek (CTKB) Q1 2026 Disappoints — EPS $-0.15 Below $-0.10 ViewsCommunity Watchlist Picks - Newser
Cytek Biosciences invites researchers to webinar unveiling novel approach to sterilizing immunity for CDI - Traders Union
CTKB: Millennium-related filers report 6.1% and 5.4% stakes (May 15, 2026) - Stock Titan
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth By Investing.com - Investing.com Australia
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth - Investing.com
Stephens cuts Cytek Biosciences stock price target on elevated costs By Investing.com - Investing.com Nigeria
Stephens cuts Cytek Biosciences stock price target on elevated costs - Investing.com UK
Stephens Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Raises Target Price to $4.75 - Moomoo
TradingKey - TradingKey
Morgan Stanley Cuts Price Target on Cytek Biosciences to $5.50 From $6, Keeps Equalweight Rating - marketscreener.com
Cytek Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-05-11 - Seeking Alpha
The strategic moves Cytek (CTKB) is making now (Investor Concern) 2026-05-11Dividend Growth - newser.com
Cytek Biosciences Balances Growth Momentum With Cost Pressures - The Globe and Mail
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytek Biosciences, Inc. (CTKB) reports Q1 loss, beats revenue estimates - MSN
Cytek Biosciences (CTKB) Margin Worsening With Q4 Loss Challenges Bullish Narratives - Sahm
Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff Pressures - TipRanks
Cytek Biosciences Q1 Revenue Increases to $44.1 Million - HarianBasis.co
Cytek (CTKB) Q1 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences, Inc.Common Stock (Nasdaq:CTKB) Stock Quote - FinancialContent
Cytek Biosciences Q1 2026 Financial Results: Revenue, Net Loss, and Key Financial Statements - Minichart
Cytek Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cytek reaffirms $205M-$212M 2026 revenue outlook as US growth rebounds - MSN
Earnings call transcript: Cytek Biosciences Q1 2026 sees revenue growth amid EPS miss - Investing.com
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Cytek Biosciences Inc. (CTKB) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Cytek Biosciences Q1 Earnings Call Highlights - Barchart.com
Cytek Biosciences (CTKB) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Cytek Biosciences, Inc. 1Q 2026: Revenue $44.14M, EPS ($0.15) — 10-Q Summary - TradingView
$44.1M quarter for Cytek Biosciences (NASDAQ: CTKB) as losses widen - Stock Titan
Cytek Biosciences | 10-Q: Q1 2026 Earnings Report - Moomoo
Cytek Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cytek Biosciences Q1 revenue rises 6%, slightly misses estimates - TradingView
Cytek adds 125 instruments as service revenue jumps 15% - Stock Titan
Cytek Biosciences Inc (CTKB) 財務データ
収益
当期純利益
現金流量
EPS
Cytek Biosciences Inc (CTKB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| McCombe William D. | Chief Financial Officer |
Jun 02 '25 |
Buy |
2.78 |
35,000 |
97,300 |
55,746 |
0.19%
1.33%
大文字化:
|
ボリューム (24 時間):